Blurbs

Leerink Partners Thinks Genocea Biosciences’ Stock is Going to Recover

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Genocea Biosciences (GNCAResearch Report) yesterday. The company’s shares closed last Monday at $0.60, close to its 52-week low of $0.39.

According to TipRanks.com, Graybosch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.6% and a 31.9% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics.

Currently, the analyst consensus on Genocea Biosciences is a Strong Buy with an average price target of $5.68, implying an 890.8% upside from current levels. In a report issued on April 10, Robert W. Baird also maintained a Buy rating on the stock with a $3.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Genocea Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $13.28 million. In comparison, last year the company had a GAAP net loss of $14.99 million.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GNCA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Read More on GNCA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos